Evid Invest
Holders — by stockHoldings — by fund

Krensavage Asset Management, LLC

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 1609251

$263,223

disclosed book value

18

positions

15.9%

largest position share

Positions, as of 2026-06-30

top 18 of 18 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1ENTAENANTA PHARMACEUTICALS INC2.9M$41,78815.9%
2JAZZ PHARMACEUTICALS PLC167,816$40,43915.4%
3UTHRUNITED THERAPEUTICS CORP69,282$37,53914.3%
4BMRNBIOMARIN PHARMACEUTICAL INC524,786$30,02811.4%
5EXELEXELIXIS INC370,693$20,1697.7%
6ABTABBOTT LABORATORIES200,000$18,1486.9%
7SNYSANOFI-ADR323,946$13,8205.3%
8SUPNSUPERNUS PHARMACEUTICALS INC280,681$13,0545%
9RAREULTRAGENYX PHARMACEUTICAL IN390,879$13,0515%
10VNDAVANDA PHARMACEUTICALS INC1.2M$7,2242.7%
11BNTXBIONTECH SE-ADR59,523$5,5392.1%
12GSKGSK PLC-SPON ADR96,729$5,0711.9%
13BIIBBIOGEN INC20,000$4,3211.6%
14REGNREGENERON PHARMACEUTICALS6,000$3,7411.4%
15EMBCEMBECTA CORP1.1M$3,7011.4%
16ARDXARDELYX INC534,523$2,7261%
17INMODE LTD120,942$1,7680.7%
18EOLSEVOLUS INC157,985$1,0960.4%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.